US Patent 10940201 Nucleic acid derivative having immunostimulatory activity
Patent 10940201 was granted and assigned to Shionogi on March, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+217 characters)
Article
Patent abstract
The purpose of the present invention is to provide double-stranded oligonucleotides comprising the CpG oligonucleotide mentioned below, as a nucleic acid derivative having an immunostimulatory activity.
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 22 Apr, 2023
Golden AI
Infobox
Edits on 5 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
109402010
Date of Patent
March 9, 2021
0Patent Application Number
159079200
Date Filed
February 28, 2018
0Official Website
Patent Primary Examiner
Edits on 28 Sep, 2022
Golden AI
Infobox
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
109402010
Date of Patent
March 9, 2021
0Patent Application Number
159079200
Date Filed
February 28, 2018
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 10 Feb, 2022
Golden AI
Edits made to:
Infobox (+10 properties)
US Patent 10940201 Nucleic acid derivative having immunostimulatory activity
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10940201
Date of patent
March 9, 2021
Patent application number
15907920
Date Filed
February 28, 2018
Patent primary examiner
Find more entities like US Patent 10940201 Nucleic acid derivative having immunostimulatory activity
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
